Compare Stocks: HRMY, CRNX, LNTH, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.65	$18.42	$9.56 ▼ $21.17	$6.28B	1.22	3.28 million shs	3.22 million shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.68	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
HRMY Harmony Biosciences	$39.60 +0.7%	$39.97	$25.52 ▼ $43.49	$2.29B	1.01	1.03 million shs	803,230 shs
LNTH Lantheus	$100.12 -0.1%	$100.48	$50.15 ▼ $111.86	$6.54B	-0.06	976,598 shs	520,129 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-3.20%	-2.43%	+12.67%	+15.45%	+89.67%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+1.59%	+99.88%
HRMY Harmony Biosciences	-0.05%	+0.19%	-6.89%	+2.96%	+45.43%
LNTH Lantheus	+0.23%	+0.65%	-0.78%	-5.48%	+93.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.65	$18.42	$9.56 ▼ $21.17	$6.28B	1.22	3.28 million shs	3.22 million shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.68	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
HRMY Harmony Biosciences	$39.60 +0.7%	$39.97	$25.52 ▼ $43.49	$2.29B	1.01	1.03 million shs	803,230 shs
LNTH Lantheus	$100.12 -0.1%	$100.48	$50.15 ▼ $111.86	$6.54B	-0.06	976,598 shs	520,129 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-3.20%	-2.43%	+12.67%	+15.45%	+89.67%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+1.59%	+99.88%
HRMY Harmony Biosciences	-0.05%	+0.19%	-6.89%	+2.96%	+45.43%
LNTH Lantheus	+0.23%	+0.65%	-0.78%	-5.48%	+93.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.80	Moderate Buy	$21.00	6.87% Upside
CRNX Crinetics Pharmaceuticals	2.13	Hold	$83.44	-1.77% Downside
HRMY Harmony Biosciences	2.36	Hold	$47.44	19.81% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.98% Upside

Current Analyst Ratings Breakdown

Latest HRMY, CRNX, LNTH, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/1/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/1/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$42.00
9/25/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/24/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/7/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.12B	2.01	$1.56 per share	12.58	($0.23) per share	-85.43
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
HRMY Harmony Biosciences	$868.45M	2.66	$3.20 per share	12.37	$15.11 per share	2.62
LNTH Lantheus	$1.54B	4.24	$6.38 per share	15.69	$16.43 per share	6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	40.10	18.19	2.31	5.05%	-584.46%	7.78%	N/A
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	12.86	9.75	0.31	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.18	17.85	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest HRMY, CRNX, LNTH, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LNTH Lantheus	$1.26	N/A	N/A	N/A	$360.82 million	N/A
11/3/2026	Q3 2026	HRMY Harmony Biosciences	$1.11	N/A	N/A	N/A	$274.55 million	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
HRMY Harmony Biosciences	0.13	3.48	3.45
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
CRNX Crinetics Pharmaceuticals	98.51%
HRMY Harmony Biosciences	86.23%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
CRNX Crinetics Pharmaceuticals	3.80%
HRMY Harmony Biosciences	11.00%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
HRMY Harmony Biosciences	293	58.24 million	51.83 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

HRMY, CRNX, LNTH, and AMRX Headlines

Recent News About These Companies

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

October 6 at 10:25 AM | globenewswire.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts

October 1, 2026 | defenseworld.netD

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Consensus Target Price of $108.11 According to Analysts

October 1, 2026 | americanbankingnews.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated "Hold" by Wall Street Analysts

October 1, 2026 | marketbeat.com

Lantheus Holdings, Inc. Receives Cms Transitional Pass-Through Status and Permanent Hcpcs Code for Pylarify Truvu

September 30, 2026 | marketscreener.comM

Lantheus Holdings, Inc. erhält CMS-Status für vorübergehende separate Erstattung und dauerhaften HCPCS-Code für Pylarify TruVu

September 30, 2026 | de.marketscreener.comD

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

September 30, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

September 29, 2026 | globenewswire.com

Lantheus Holdings, Inc. Announces First Patient Dosed In SPARROW Phase 2/3 Registrational Trial Evaluating LNTH-2401 In Prostate Cancer

September 28, 2026 | marketscreener.comM

Lantheus Holdings, Inc.: Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | finanznachrichten.de

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | globenewswire.com

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

September 26, 2026 | finance.yahoo.com

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

September 25, 2026 | finance.yahoo.com

Lantheus (NASDAQ:LNTH) Stock Price Breaks Below Fifty Day Moving Average - Here's What Happened

September 25, 2026 | marketbeat.com

FDA approval for Lantheus’ Bravnetsa

September 24, 2026 | thepharmaletter.comT

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 24, 2026 | globenewswire.com

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

September 23, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs

September 22, 2026 | marketscreener.comM

FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

September 22, 2026 | streetinsider.com

Lantheus Holdings stock faces a new Curium review window

September 22, 2026 | ad-hoc-news.deA

FDA Approves Lantheus' Bravnetsa As Equivalent To Lutathera For Neuroendocrine Tumors

September 22, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, CRNX, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$19.65 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$19.43 -0.22 (-1.12%)

As of 07:30 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Crinetics Pharmaceuticals NASDAQ:CRNX

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Harmony Biosciences NASDAQ:HRMY

$39.60 +0.26 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$39.63 +0.03 (+0.08%)

As of 07:30 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Lantheus NASDAQ:LNTH

$100.12 -0.06 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$100.12 0.00 (0.00%)

As of 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRMY, CRNX, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRMY, CRNX, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRMY, CRNX, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, CRNX, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Crinetics Pharmaceuticals NASDAQ:CRNX

Harmony Biosciences NASDAQ:HRMY

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRMY, CRNX, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRMY, CRNX, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRMY, CRNX, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, CRNX, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Crinetics Pharmaceuticals NASDAQ:CRNX

Harmony Biosciences NASDAQ:HRMY

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools